Monoclonal antibodies with cytotoxic reactivities against human gliomas.
Monoclonal antibodies (MAb's) reactive with human malignant glioma cells were derived from mice inoculated with cells from fresh glioma tissue. Seven MAb's were selected for study based on their high-level binding in immunoperoxidase and immunofluorescence assay to most of the glioma tissues derived from various patients and based on the absence of binding to normal bone marrow cells. Four of the seven MAb's did not bind to any of the four normal brain tissues tested, whereas three MAb's bound to one or two of these tissues. Two MAb's bound to the surfaces of cultured glioma cells in radioimmunoassay. One of these MAb's (AS-AY1, immunoglobulin (Ig)(G1) lysed cultured glioma cells with human lymphocytes or murine macrophages as effector cells; the other MAb (AS-AY2, IgM) was reactive in complement-dependent cytotoxicity assay. These two MAb's therefore seem especially promising reagents in approaches to immunotherapy of human malignant glioma.
Nanda
A
A
Department of Neurosurgery, Hahnemann University, Philadelphia, Pennsylvania.
Liwnicz
B
B
Atkinson
B F
BF
Sela
B A
BA
Takahashi
H
H
Belser
P H
PH
Black
P
P
Koprowski
H
H
Herlyn
D
D
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000920:Antibody-Dependent Cell Cytotoxicity; D001773:Blood Cells / Q000276:immunology; D002462:Cell Membrane / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005910:Glioma / Q000276:immunology*; D006801:Humans; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D003165:Complement System Proteins